SCHEMBL6835188

SCHEMBL6835188

c1ccc(-c2nc3c([nH]2)-c2ccccc2CCC3)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 9/20 0.61
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
MAPK13 O15264 3/20 0.39
MAPK12 P53778 3/20 0.39
MAPK11 Q15759 3/20 0.39
MAPK14 Q16539 3/20 0.39
RAF1 P04049 2/20 0.39
MAPK9 P45984 1/20 0.39
CYP2A6 P11509 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6836970 0.90 NPY5R (0.64) NPY5RCDK1MAPK13MAPK12MAPK11
SCHEMBL6831691 0.86 NPY5R (0.66) NPY5RKMT2ANPC1RAB9A
SCHEMBL6835211 0.84 NPY5R (0.66) NPY5RKMT2ANPC1RAB9AMAPK13
SCHEMBL6837109 0.81 NPY5R (0.64) NPY5RKMT2ANPC1RAB9A
SCHEMBL6567123 0.80 NPY5R (0.41) NPY5RKMT2AL3MBTL1CCNB2CDK1
SCHEMBL6835593 0.72 NPY5R (0.34) NPY5RBCHEACHECCNB2CDK1
SCHEMBL6835195 0.72 NPY5R (0.48) NPY5RMAPK13MAPK12MAPK11MAPK14
SCHEMBL6834673 0.72 NPY5R (0.67) NPY5RMAPK13MAPK12MAPK11MAPK14
SCHEMBL6835539 0.72 NPY5R (0.67) NPY5RKMT2ANPC1RAB9AMAPK13
SCHEMBL6836929 0.71 NPY5R (0.69) NPY5RKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198791-A1 Fused imidazole derivative FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198791-A1 Fused imidazole derivative H1-0, H1-5, H1-3 NPY5R 983/4885BCHE 2905/4885ACHE 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.